Traditionally, MMR protein status is screened via immunohistochemical (IHC) staining for proteins such as MLH1, MSH2, MSH6, and PMS2. These proteins play essential roles in DNA repair through the recognition and excision of mismatched bases during DNA replication. When defective, the resultant failure to maintain genomic integrity leads to MSI, a hallmark of certain cancer subtypes marked by frequent insertion or deletion mutations in repetitive DNA sequences. Identifying MSI is critical because tumors exhibiting high MSI (MSI-H) often respond robustly to immune checkpoint blockade, a treatment revolutionizing cancer care in the last decade.

However, the IHC evaluation of MMR proteins in gastric cancer is confounded by intratumoral heterogeneity—where areas within the same tumor display varying levels or patterns of protein expression. This variability can manifest as a (sub)clonal staining pattern, where clusters of tumor cells retain protein expression while adjacent groups lose it, complicating the binary interpretation of proficient versus deficient MMR status. Zhong et al.’s study confronts this challenge by meticulously examining a large cohort of gastric cancer samples, revealing how such heterogeneity impacts MSI diagnosis.

The study examined 1,049 gastric adenocarcinoma cases collected from the First Affiliated Hospital of Zhejiang University School of Medicine over six years. Among these, seven cases displayed marked heterogeneous MMR protein staining characterized by abrupt loss of staining juxtaposed with retained areas within the same tumor specimen. Previous paradigm may have classified these heterogeneous cases as MMR proficient (pMMR) due to dominant intact staining regions, potentially missing MSI-H tumors. To address this, the team employed tumor microdissection, isolating the staining-lost regions for precise molecular MSI testing.

Remarkably, the microdissected tumor areas with lost MMR staining consistently demonstrated MSI-H status despite the overarching categorization as pMMR by conventional IHC. This breakthrough highlights how disregarding intratumoral heterogeneity could lead to underdiagnosis of MSI-H tumors, depriving patients of optimized immunotherapies. The work advocates for integrative diagnostic strategies that combine detailed IHC pattern analysis with targeted molecular assays to safeguard against false negatives.

Beyond technical diagnostic implications, Zhong et al. further interrogated the relationship between MSI status and clinical-pathological features in a carefully selected cohort of 107 patients. Their data revealed a spectrum of distinct characteristics associated with MSI-H tumors in gastric cancer. These tumors more commonly occurred in older patients, predominantly localized to the distal stomach, and were histologically classified as intestinal-type adenocarcinomas. Strikingly, these MSI-H tumors also exhibited a reduced incidence of lymphatic metastasis and perineural invasion, as well as lower clinical staging.

While these clinicopathological features align with findings in other cancers with MSI, the study underscored the prognostic nuances in gastric cancer. Although no significant difference in 45-month disease-free survival was observed between MSI and microsatellite stable (MSS) groups, multivariate analysis noted patient age and pTNM stage as robust prognostic factors influencing progression-free survival. This indicates that MSI status, though pivotal in guiding immunotherapy decisions, may not alone dictate clinical outcomes, warranting a holistic appraisal of patient and tumor characteristics.

The implications of this research ripple into the clinical realm. Accurate MSI detection directly informs therapeutic approaches, particularly the use of immune checkpoint inhibitors, which have transformed the treatment landscape for many MSI-H malignancies. As such, meticulous characterization and reporting of MMR protein staining heterogeneity should become a standard practice. This nuanced approach ensures that patients receive precise diagnoses and the benefit of emerging personalized immunotherapy regimens.

Zhong et al. also emphasize the utility of quantifying the extent of heterogeneous staining rather than relying solely on present/absent dichotomies. Advanced image analysis and pathologist training are called upon to improve interpretation fidelity and reproducibility across institutions. The study thus bridges molecular pathology with clinical oncology, laying the groundwork for an integrated diagnostic framework that can capture the diverse biology of gastric cancer.

Future efforts will undoubtedly build on these insights, investigating the genetic underpinnings driving MMR heterogeneity and exploring whether therapeutic responses differ between homogeneous and heterogeneous MSI-H tumors. Additionally, refining biopsy sampling protocols to capture representative tumor regions could mitigate diagnostic pitfalls inherent in intratumoral variability.

In conclusion, the work by Zhong and colleagues marks a seminal advance in our understanding of mismatch repair protein expression variability in gastric cancer. By revealing the hidden MSI-H status within tumors masked by heterogeneous MMR IHC patterns, the study advocates for a paradigm shift in pathological assessment and personalized oncology. Such findings not only refine diagnostic precision but also potentiate tailored immunotherapy strategies, heralding a new era in gastric cancer management.

With gastric cancer remaining a leading cause of cancer mortality worldwide, insights into molecular heterogeneity and its clinical ramifications are critical. This study exemplifies how rigorous translational research can uncover concealed tumor complexities and steer precision medicine forward. As immunotherapy continues its ascendancy, ensuring that diagnostic tools match molecular intricacies will be paramount to improving survival and quality of life for gastric cancer patients globally.

The future beckons an era where pathology reports encompass detailed characterization of MMR protein expression patterns, MSI status confirmed by molecular methods, and integrated clinical prognostic modeling. Zhong et al.’s work is a clarion call to the oncology community: embrace complexity within gastric tumors to unlock the full potential of immune-based therapies and ultimately transform patient care in this challenging malignancy.

Subject of Research: Heterogeneity of mismatch repair protein expression and its clinical and prognostic implications in gastric cancer, with a focus on microsatellite instability status.

Article Title: Deciphering mismatch repair protein expression variability in gastric cancer: clinical and prognostic implications.

Article References:
Zhong, F., Zhang, M., Xu, L. et al. Deciphering mismatch repair protein expression variability in gastric cancer: clinical and prognostic implications. BMC Cancer 25, 1699 (2025). https://doi.org/10.1186/s12885-025-14857-8

Image Credits: Scienmag.com

DOI: 10.1186/s12885-025-14857-8 (Published 04 November 2025)

At the molecular level, CRC development is conceptualized as a multistep evolutionary process characterized by sequential genetic insults. Key molecular pathways such as the adenoma-carcinoma sequence form the backbone of tumorigenesis. Mutations in pivotal genes—including APC, KRAS, and TP53—disrupt the regulatory machinery of cell growth and apoptosis. Additionally, aberrations in signaling networks such as WNT and TGF-β pathways exacerbate malignant transformation. Intriguingly, heterogeneity within CRC tumors is categorized into molecular subtypes—microsatellite instability (MSI), chromosomal instability (CIN), and consensus molecular subtypes (CMS)—each with distinct biological behaviors and prognostic implications. This granular understanding paves the way for precision diagnostics and tailored therapeutic interventions.

Epidemiological data underscore the multifactorial etiology of CRC, where both genetic predispositions and environmental exposures interplay. Risk elements such as advancing age, hereditary syndromes including Lynch syndrome and familial adenomatous polyposis, and chronic conditions like inflammatory bowel disease create vulnerability to malignant transformation. Concurrently, lifestyle factors wield significant influence; sedentary habits, tobacco usage, excessive alcohol consumption, obesity, and diets rich in red and processed meats elevate CRC risk. Emerging research also implicates complex alterations in gut microbiota composition and persistent inflammatory states as catalysts in colorectal carcinogenesis, revealing new horizons for innovative preventive strategies.

In the landscape of CRC detection, point-of-care diagnostic modalities have dramatically evolved, striving for accuracy, accessibility, and patient compliance. Non-invasive fecal assays such as the Fecal Occult Blood Test (FOBT) have historically provided initial screening options. However, limitations in specificity and false-positive rates, aggravated by dietary interferences, have catalyzed the development of more sensitive assays. The Fecal Immunochemical Test (FIT), targeting human hemoglobin, supplants FOBT by delivering enhanced specificity without dietary restrictions. Furthermore, fecal DNA testing exploits molecular markers including mutations in KRAS and methylation of BMP3, intensifying diagnostic precision, though challenges in false positives necessitate meticulous clinical interpretation.

Beyond stool-based diagnostics, blood-based biomarkers represent a burgeoning frontier in non-invasive CRC detection. The Septin9 assay, targeting methylated DNA signatures circulating in the bloodstream, epitomizes this approach yet grapples with limited sensitivity in detecting pre-malignant adenomas. Expanding this paradigm, liquid biopsy technologies analyze circulating tumor DNA (ctDNA), providing dynamic insights into tumor genomics and real-time disease monitoring. Despite promising clinical applications, liquid biopsy remains complementary to existing screening frameworks due to constraints in sensitivity and cost-effectiveness.

Endoscopic interventions retain their status as the definitive CRC diagnostic and interventional tools. Colonoscopy, the gold standard, offers direct visualization, enabling both detection and therapeutic excision of polyps, distinctly reducing cancer incidence. However, the invasiveness, requisite bowel preparation, and associated patient discomfort pose significant barriers to widespread screening adherence. Alternative approaches, including sigmoidoscopy and capsule endoscopy, address certain limitations but are constrained by coverage gaps and diagnostic comprehensiveness, particularly for proximal colon lesions.

Radiological techniques complement endoscopic methods, offering non-invasive visualization of the colorectal tract. Computed Tomography (CT) colonography generates three-dimensional images of the colon, facilitating polyp detection without the invasion of traditional endoscopy. Nevertheless, the need for bowel cleansing and potential omission of smaller lesions restrict its applicability. Historic methods such as barium enema have largely receded due to inferior sensitivity and specificity compared to contemporary imaging and endoscopy.

Recent technological advancements are revolutionizing CRC diagnostics by integrating cutting-edge molecular and computational platforms. Single-cell sequencing (SCS) disentangles intratumoral heterogeneity, charting the landscape of genetic alterations at unprecedented resolution, vital for understanding tumor evolution and therapeutic resistance. Complementing this, spatial transcriptomics (ST) contextualizes gene expression within the histological architecture, offering nuanced subtype stratification and potential prognostic biomarkers. Artificial intelligence (AI) applications are redefining endoscopic practice by enhancing polyp detection accuracy, automating histopathological evaluations, and synthesizing multi-omic datasets into comprehensive risk models, heralding a new era of personalized medicine.

Lifestyle modification remains a cornerstone in mitigating CRC risk. Establishing dietary patterns rich in fiber while limiting red and processed meat intake, fostering regular physical activity, and abstaining from tobacco and excessive alcohol consumption significantly decrease disease incidence. In parallel, chemopreventive research explores natural compounds and prebiotics as adjuvants to fortify the intestinal environment and inhibit carcinogenic pathways, potentially complementing traditional prevention paradigms.

Despite the progress in screening technology and understanding CRC biology, substantial hurdles persist in global implementation. Screening adherence varies widely across populations due to socioeconomic factors, access disparities, and public awareness. The lack of uniform international guidelines confounds standardized care delivery. Moreover, current methods insufficiently detect early, flat, or sessile lesions, necessitating innovations that balance sensitivity with minimally invasive patient experiences.

Looking ahead, the integration of multi-omics data with advanced analytics promises transformative potential in CRC management. A precision screening framework combining genetic, epigenetic, proteomic, and metabolomic profiles could identify high-risk individuals with unparalleled specificity. Coupled with AI-driven interpretation, such an approach would enable real-time, adaptive screening intervals, and individualized preventive strategies. Simultaneously, public health initiatives must amplify education and access to catalyze lifestyle changes and equitable screening uptake worldwide.

In conclusion, colorectal cancer remains a formidable health challenge with significant morbidity and mortality on a global scale. However, multidisciplinary advances spanning molecular biology, diagnostic technology, and computational intelligence provide a beacon of hope. By converging innovative screening modalities, personalized interventions, and proactive lifestyle management, the medical community edges closer to the ultimate goal of reducing CRC burden and enhancing patient survival.

Subject of Research: Advancements in screening and point-of-care diagnostics for colorectal cancer

Article Title: An Overview of Advancements in Screening Methods and Point-of-care Diagnostics for Colorectal Cancer

News Publication Date: 28-May-2025

Web References:
https://www.xiahepublishing.com/journal/csp
http://dx.doi.org/10.14218/CSP.2025.00006

Image Credits: Sandip V. Pawar

Keywords: Colorectal cancer, Cancer, Screening, Point-of-care diagnostics, Molecular subtypes, Single-cell sequencing, Artificial intelligence